Hugel Reports Record First-Quarter Sales of 89.8 Billion KRW

Hugel, a global total medical aesthetics company, reported consolidated financial results for the first quarter of this year, posting sales of 89.8 billion KRW, operating profit of 39 billion KRW, and net profit of 30.9 billion KRW. Compared to the same period last year, these figures represent increases of 20.9%, 62.6%, and 35.9%, respectively, marking the highest first-quarter performance in the company's history.

This growth in performance was driven by balanced growth across all product categories owned by Hugel.

First, sales of the botulinum toxin product 'Botulax' reached 40.7 billion KRW, accounting for 45% of total sales and representing an 18.8% increase compared to the same period last year. By region, the Asia-Pacific area (including China, Australia, and Taiwan) recorded the highest growth, with a 54% year-on-year increase.

HA fillers ('The Chaeum' and 'Bylizen Skin Booster HA') also achieved sales of 34.4 billion KRW, up 17.7% from the same period last year. Strong sales were notable not only in the domestic market but also in the Asia-Pacific, North and South America, and Europe.

The cosmetics segment ('Wellage' and 'BylizenBR') also recorded remarkable results, with sales of 13.2 billion KRW, up 39.3% from the previous year. The derma cosmetic brand 'Wellage' and the high-end cosmetic brand 'BylizenBR' have continued to expand consumer touchpoints through the successive launch of new products and diversification of domestic and overseas distribution channels.

A Hugel representative stated, "Thanks to company-wide efforts, all Hugel product lines have continued to perform well in both domestic and international markets, achieving another record-breaking first-quarter result," adding, "We will work to further solidify our position in the global market by leveraging upcoming shipments to the United States and expansion into the Middle East in the second quarter."

Meanwhile, Hugel's board of directors resolved on this day to cancel 300,000 shares of treasury stock. This is in line with a strong shareholder return policy, with the cancellation scheduled for the 15th of this month.